Please ensure Javascript is enabled for purposes of website accessibility

Why Rigel Pharmaceuticals Stock Jumped Today

By Prosper Junior Bakiny - Apr 13, 2021 at 4:02PM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

The company announced positive results from an important COVID-19 clinical study.

What happened?

Shares of Rigel Pharmaceuticals (RIGL 10.62%) shot higher on Tuesday after the biotech announced positive topline data from a phase 2 clinical trial for fostamatinib as a treatment for hospitalized COVID-19 patients. The stock closed the trading day up by 16.8%, after having been up by as much as 18.8% late in the session. 

So what

Fostamatinib is already approved in the U.S. and elsewhere as a treatment for adult chronic immune thrombocytopenia. Rigel Pharmaceuticals is currently running a phase 2 study for the medicine in COVID-19 patients in collaboration with the National Institutes of Health (NIH) and Inova Health System, a nonprofit healthcare provider headquartered in Virginia. The trial enrolled 59 hospitalized COVID-19 patients, each of whom received either fostamatinib plus standard of care or a placebo plus standard of care twice a day for 14 days.

Microscopic view of the coronavirus.

Image source: Getty Images.

First, fostamatinib met its primary safety endpoint during the trial. Also, the group of patients who received the medicine had recorded zero deaths at day 29, compared to three deaths in the placebo group.

"Taken altogether, the results of this trial suggest fostamatinib may be a useful addition to improve the outcome of severe and critically ill COVID-19 patients who are at the highest risk of death despite treatment with the best conventional therapies under the current standard of care (including remdesivir and steroids)," said Rigel Pharmaceuticals Chief Medical Officer Wolfgang Dummer.

Now what

With these positive results to show off, Rigel Pharmaceuticals plans on discussing a potential emergency use authorization with the Food and Drug Administration for fostamatinib as a treatment for COVID-19. Although the rollout of vaccines continues, the need for effective treatments for the disease won't dissipate anytime soon. If the healthcare company can earn a conditional green light from regulators for its potential coronavirus medicine, that will likely have a meaningful impact on its financial results. 

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Rigel Pharmaceuticals, Inc. Stock Quote
Rigel Pharmaceuticals, Inc.
$1.25 (10.62%) $0.12

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
S&P 500 Returns

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 07/01/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.